Drug Details

General Information of the Drug (ID: DR2819)
Name
Hydrochlorothiazide
Synonyms
hydrochlorothiazide; 58-93-5; HCTZ; Esidrix; Hypothiazide; Oretic; Dichlotiazid; Hidrotiazida; Hydrochlorothiazid; Hydrochlorthiazide; Hydrodiuretic; Hydrosaluric; Servithiazid; Aquarills; Aquarius; Dichlotride; Diclotride; Disalunil; Hypothiazid; Idrotiazide; Maschitt; Megadiuril; Newtolide; Thiuretic; Vetidrex; Drenol; Esidrex; Hidril; Hydril; Nefrix; Chlorosulthiadil; Hidrochlortiazid; Hydro-Diuril; Hydro-Aquil; Dihydrochlorothiazide; Jen-Diril; HydroDIURIL; Dihydrochlorothiazid; Dihydrochlorothiazidum; Apresazide; Carozide; Chlorzide; Dichlorosal; Hidroronol; Hydrothide; Hydrozide; Moduretic; Neoflumen; Urodiazin; Bremil; Cidrex; Diaqua; Direma; Dyazide; Fluvin; Ivaugan; Panurin; Ro-hydrazide; Neo-codema; Acuretic; Caplaril; Hydrocot; Microzide; Thlaretic; Timolide; Aquazide H; Lotensin HCT; 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydrochlorothiazide; Thiaretic; Vaseretic; Ziac; Zide; Apo-Hydro; Lopressor HCT; Hydro-D; Hydrochlorothiazidum; Unipres; Dihydrochlorurit; Dihydrochlorurite; Hidroclorotiazida; Su 5879; Aldactazide; Inderide; Maxzide; Prinzide; Hydrochlorothiazide Intensol; NCI-C55925; component of Cyclex; component of Esimil; Esidrix (TN); Ser-Ap-Es; C7H8ClN3O4S2; component of Aldoril; component of Dyazide; component of Caplaril; HCZ; Chlorsulfonamidodihydrobenzothiadiazine dioxide; component of Aldactazide; UNII-0J48LPH2TH; component of Butizide Prestabs; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1,1-dioxide; Dichlothiazide; MFCD00051765; Diu-melusin; 0J48LPH2TH; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide; 6-Chloro-3,4-dihydro-(2H)-1,2,4-benzothiadiazine-7-sulfonamide 1,1-Dioxide; MLS000069619; CHEBI:5778; Chlorizide; Disothiazid; Hidrosaluretil; Novodiurex; Spironazide; Acesistem; Acuilix; Aldazida; Briazide; Catiazida; Chlothia; Clorana; Condiuren; Dihydran; Diurogen; Dixidrasi; Esoidrina; H.H. 25/25; H.H. 50/50; Hyclosid; Indroclor; Manuril; Medozide; Mictrin; Mikorten; Modurcen; Natrinax; Pantemon; Saldiuril; Selozide; Tandiur; Urozide; Didral; Hytrid; Nefrol; Unazid; Hidro-Niagrin; Hydro-Saluric; Raunova Plus; 3,4-Dihydro-6-chloro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; Concor Plus; Aquazide-H; Neo-Flumen; Neo-Minzil; 6-Chloro-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; Hydro Par; NSC53477; Hydro-T; Hydrochlorthiazidum; NSC-53477; HCT; HCT-Isis; CAS-58-93-5; Mazide 25 mg; NCGC00015508-08; Hydrochlorat; Hydrochlorot; SMR000035778; Idroclorotiazide; Diu 25 Vigt; Hydrex-semi; Aldactazide 25/25; Aldectazide 50/50; Dihydroxychlorothiazidum; DSSTox_CID_713; Inderide 80/25; Hydrochlorothiazide form II; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-,1,1-dioxide; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide; 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide; 6-chloro-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-sulfonamide 1,1-dioxide; Idroclorotiazide [DCIT]; DSSTox_RID_75752; DSSTox_GSID_20713; Hydrochlorzide; Ezide; Hydrozide Injection, Veterinary; Hidroclorotiazida [INN-Spanish]; Hydrochlorothiazidum [INN-Latin]; 6-Chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide; Microzide (TN); CCRIS 2082; HSDB 3096; SR-01000000119; EINECS 200-403-3; NSC 53477; BRN 0625101; Hydrokraft; Idrodiuvis; Aquazide; Manschitt; Urirex; HydroPar; 6-chloro-1,1-dioxo-2H,3H,4H-benzo[e]1,2,4-thiadiazine-7-sulfonamide; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1?^{6},2,4-benzothiadiazine-7-sulfonamide; Prestwick_263; Hydrochloro Thiazide; Hyzaar (Salt/Mix); Aldoril (Salt/Mix); Dutoprol (Salt/Mix); Inderide (Salt/Mix); Prinzide (Salt/Mix); Accuretic (Salt/Mix); Hydropres (Salt/Mix); Thiazide, hydrochloro-; Hydrochlorothiazide [USP:INN:BAN:JAN]; Spectrum_000877; Opera_ID_168; Maybridge1_004336; Prestwick0_000009; Prestwick1_000009; Prestwick2_000009; Prestwick3_000009; Spectrum2_001040; Spectrum3_000456; Spectrum4_000006; Spectrum5_000824; Lopac-H-4759; CHEMBL435; Tekturna HCT (Salt/Mix); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1, 1-dioxide; H 4759; cid_3639; SCHEMBL9349; Hydrochlorothiazide-13C-d2; Lopac0_000614; Oprea1_357174; BSPBio_000017; BSPBio_002132; KBioGR_000351; KBioSS_001357; AF-614/30832002; ARONIS24316; BIDD:GT0153; DivK1c_000289; SPECTRUM1500335; BMCL182567 Compound 6a; SPBio_001259; SPBio_001938; BPBio1_000019; GTPL4836; Hydrochlorothiazide, crystalline; DTXSID2020713; BDBM13076; component of Dyazide (Salt/Mix); HMS500O11; HMS553N04; KBio1_000289; KBio2_001357; KBio2_003925; KBio2_006493; KBio3_001352; component of Caplaril (Salt/Mix); NINDS_000289; HMS1568A19; HMS1920D19; HMS2091L05; HMS2095A19; HMS2235I09; HMS3259O17; HMS3261L10; HMS3370P11; HMS3428A05; HMS3655M21; HMS3712A19; Pharmakon1600-01500335; ZINC896569; BCP22001; EBD18905; HY-B0252; JFD00715; Tox21_110165; Tox21_201565; Tox21_300292; Tox21_500614; 3,4-dihydro-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide; CCG-40240; NSC757059; s1708; SBB056984; STK315354; 3,2,4-benzothiadiazine-1,1-dioxide; Hydrochlorothiazide (JP17/USP/INN); AKOS000121373; Tox21_110165_1; AC-8114; DB00999; LP00614; MCULE-6585933943; NC00510; NSC-757059; PS-3162; SDCCGSBI-0050596.P005; SU-5879; IDI1_000289; WLN: T66 BSWM EM DHJ HG ISZW; NCGC00015508-01; NCGC00015508-02; NCGC00015508-03; NCGC00015508-04; NCGC00015508-05; NCGC00015508-06; NCGC00015508-07; NCGC00015508-09; NCGC00015508-10; NCGC00015508-11; NCGC00015508-12; NCGC00015508-13; NCGC00015508-14; NCGC00015508-16; NCGC00015508-17; NCGC00015508-25; NCGC00021906-03; NCGC00021906-04; NCGC00021906-05; NCGC00021906-06; NCGC00021906-07; NCGC00021906-08; NCGC00254017-01; NCGC00259114-01; NCGC00261299-01; NCI60_004317; ST033548; component of Butizide Prestabs (Salt/Mix); Hydrochlorothiazide 1.0 mg/ml in Methanol; SBI-0050596.P004; AB00052012; EU-0100614; FT-0650564; SW196569-3; 6-Chloro-3,2,4-benzothiadiazine 1,1-dioxide; A19550; C07041; D00340; J10079; AB00052012-15; AB00052012_16; AB00052012_17; 051H765; Hydrochlorothiazide 100 microg/mL in Acetonitrile; Q423930; Hydrochlorothiazide, meets USP testing specifications; Q-201210; SR-01000000119-2; SR-01000000119-4; SR-01000000119-6; BRD-K13078532-001-05-2; Z56347248; 6-Chloro-3,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-3,2,4-benzothiadiazine 1,1-dioxide; Hydrochlorothiazide, drug standard, 1.0 mg/mL in methanol; 6-chloro-3,4-dihydro-1,1-dioxo-7-sulfamoyl-1,2,4-benzothiadiazine; Hydrochlorothiazide, British Pharmacopoeia (BP) Reference Standard; Hydrochlorothiazide, European Pharmacopoeia (EP) Reference Standard; 3,4-Dihydro-6-chloro-7-sulfamyl-1,2, 4-benzothiadiazine-1,1-dioxide; 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulphonamide-1,1-dioxide; 6-Chloro-3,4-dihydro-7-sulfamoyl-2H-1,2, 4-benzothiadiazine 1,1-dioxide; 6-Chloro-7-sulfamoyl-3, 4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-7-sulfamoyl-3,4-dihydro-(2H)-1,2,4-benzothiadiazine 1,1-Dioxide; 6-Chloro-7-sulfamoyl-3,4-dihydrobenzo-1,2,4-thiadiazine-1,1-dioxide; Hydrochlorothiazide, United States Pharmacopeia (USP) Reference Standard; 2H-1,2, 4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1, 1-dioxide; 2H-1,2,4-Benzothiadiazine, 6-chloro-3,4-dihydro-7-sulfamoyl-2, 1,1-dioxide; 2H-1,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1,1-dioxide; 6-chloro-1,1-dioxo-1,2,3,4-tetrahydro-1lambda,2,4-benzothiadiazine-7-sulfonamide; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1$l^{6,2,4-benzothiadiazine-7-sulfonamide; 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1, 1-dioxide; 7-(Aminosulfonyl)-6-chloro-3,4-dihydro-(2H)-1,2,4-benzothiadiazine 1,1-Dioxide; Hydrochlorothiazide for peak identification, European Pharmacopoeia (EP) Reference Standard; Hydrochlorothiazide, Pharmaceutical Secondary Standard; Certified Reference Material; 125727-50-6; 3,4-Dihydro-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine-1,1-dioxide; 3,4-Dihydrochlorothiazide; Hydrochlorothiazide solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
    Click to Show/Hide
Molecular Type
Small molecule
Disease Hypertension [ICD-11: BA00] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 70-490 mcg/L
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-5 h
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability
Bioavailability
The bioavailability of drug is 65-75%
Clearance
The renal clearance of drug is 285 mL/min
Elimination
100% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 5.6 - 14.8 hours
Metabolism
The drug is not metabolised
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.18424 micromolar/kg/day
Vd
The volume of distribution (Vd) of drug is 0.83-4.19 L/kg
Water Solubility
The ability of drug to dissolve in water is measured as 0.6 mg/mL
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C7H8ClN3O4S2
PubChem CID
3639
Canonical SMILES
C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl
InChI
1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)
InChIKey
JZUFKLXOESDKRF-UHFFFAOYSA-N
CAS Number
CAS 58-93-5
ChEBI ID
CHEBI:5778
TTD Drug ID
D0U4UQ
DrugBank ID
DB00999
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Moxonidine      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Clinical trial
                    Experimental
                    Result(s)		 This profile of moxonidine is highly comparable to a standard first-line antihypertensive drug such as hydrochlorothiazide, without sacrificing tolerance and safety for increased efficacy, in combination with hydrochlorothiazide.
Target and Pathway
Target(s) Angiotensin-converting enzyme 1 (ACE1)  Molecule Info  [3]
KEGG Pathway Renin-angiotensin system Click to Show/Hide
2 Chagas disease (American trypanosomiasis)
3 Hypertrophic cardiomyopathy (HCM)
Pathwhiz Pathway Angiotensin Metabolism Click to Show/Hide
Reactome Metabolism of Angiotensinogen to Angiotensins Click to Show/Hide
WikiPathways ACE Inhibitor Pathway Click to Show/Hide
2 Metabolism of Angiotensinogen to Angiotensins
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4836).
Reference 2 Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol. 1994;24 Suppl 1:S25-8.
Reference 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link